Techulon, Inc. Awarded $1.9 Million to Defeat “Superbugs”



BLACKSBURG, Va.–(BUSINESS WIRE)–Techulon, Inc. announced today that it has been selected by the Defense Advanced Research Projects Agency (DARPA) for a Phase II contract to advance its therapeutic program for multi-drug resistant bacteria, or ‘superbugs.’ This award drives Techulon’s development of a nanotherapeutic agent that will give the Department of Defense and hospitals the ability to rapidly respond and treat patients with life-threatening multi-drug resistant infections. Techulon successfully completed an early feasibility program of its technology platform in 2012 with DARPA leading up to the current award.


Geef een reactie

Vul je gegevens in of klik op een icoon om in te loggen. logo

Je reageert onder je account. Log uit /  Bijwerken )

Google+ photo

Je reageert onder je Google+ account. Log uit /  Bijwerken )


Je reageert onder je Twitter account. Log uit /  Bijwerken )

Facebook foto

Je reageert onder je Facebook account. Log uit /  Bijwerken )


Verbinden met %s